Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Shire news

14 Dec 2007 Shire expands its gastrointestinal portfolio through in-licensing Celiac disease Phase 2 product from Alba Therapeutics Corporation (83KB PDF)
13 Dec 2007 Board Changes (77KB PDF)
06 Dec 2007 Permission granted to challenge the High Court ruling to restrict Alzheimers’ drugs access on the NHS (16KB PDF)
27 Nov 2007 Shire Pharmaceuticals donates over 400 laptops (21KB PDF)
20 Nov 2007 Shire Human Genetic Therapies Appoints Dr. Whaijen Soo to Manage the R&D of its Expanding Treatment Portfolio (31KB PDF)
13 Nov 2007 Shire pleased with Vyvanse growth - Reuters Health Summit (video)
08 Nov 2007 Shire expands its Human Genetic Therapies pipeline through in-licensing agreement with Amicus Therapeutics (86KB PDF)
05 Nov 2007 New non-clinical data links DYNEPO® (epoetin delta) to Reduced Angiogenic Potential (87KB PDF)
01 Nov 2007 Further upgrade to 2007 financial guidance based on strong revenue growth; VYVANSE™ demand on track (255KB PDF)
31 Oct 2007 David Mott appointed Non Executive Director at Shire (70KB PDF)
25 Oct 2007 Shire launches clinical study results website (30KB PDF)
17 Oct 2007 Third quarter 2007 results date notification (169KB PDF)
08 Oct 2007 Reinforcing strategic focus on growth-driving global products (71KB PDF)
04 Oct 2007 Shire’s ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome (72KB PDF)
01 Oct 2007 Shire to support appeal against outcome of Judicial Review of NICE guidance which denies newly diagnosed patients with mild Alzheimer's disease access to drugs on the NHS (23KB PDF)
28 Sep 2007 Families Invited to Celebrate "Shire Day" at Boston Children’s Museum (20KB PDF)
28 Sep 2007 Shire launches Clinical Study Results Database
24 Sep 2007 Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business (81KB PDF)
13 Sep 2007 IFRS Information – First half of 2007 (140KB PDF)
12 Sep 2007 Notification of the Exercise of an Option and Sale of Shares by a Director/PDMR. (28KB PDF)
12 Sep 2007 Notification of the Exercise of an Option and Sale of Shares by a PDMR. (28KB PDF)
12 Sep 2007 Statistically significant efficacy of Juvista® demonstrated in phase 2 trial using drug substance manufactured by Lonza Biologics (103KB PDF)
07 Sep 2007 Revised NICE Guidance on Alzheimer's disease (AD) confirms reliance on the MMSE1 for majority of patients and continued exclusion from NHS treatment for those with mild AD (24KB PDF)
05 Sep 2007 New partnership promises bright future for organic chemistry in the UK
04 Sep 2007 Shire voluntarily withdraws a limited portion of DAYTRANA™ (methylphenidate transdermal system) patches (69KB PDF)
15 Aug 2007 Shire supports Canada's Access to Medicines Regime (34KB PDF)
15 Aug 2007 Expiry of Hart-Scott-Rodino waiting period for JUVISTA® (human TGFβ3) (108KB PDF)
10 Aug 2007 Majority of patients with mild Alzheimer’s disease will remain excluded from NHS treatment despite revisions to NICE Guidance (24KB PDF)
10 Aug 2007 Uncertainty remains for newly diagnosed patients with mild Alzheimer’s disease and their families as the Judicial Review judgement is revealed (20KB PDF)
02 Aug 2007 Total Voting Rights (18KB PDF)
31 Jul 2007 CNBC interview with Matthew Emmens, CEO, following Shire’s Q2 results (video)
27 Jul 2007 Application for Share Listing (17KB PDF)
26 Jul 2007 2007 guidance upgraded as revenue growth accelerates (196KB PDF)
25 Jul 2007 Shire Board Changes (34KB PDF)
19 Jul 2007 Second quarter 2007 results – Timing of investor / analyst meeting changed to 14:30 BST / 9:30 EDT (20KB PDF)
18 Jul 2007 Second quarter 2007 results date notification - 26 July 2007 (21KB PDF)
02 Jul 2007 Total Voting Rights (18KB PDF)
29 Jun 2007 Shire Announces Filing of VYVANSE™ (lisdexamfetamine dimesylate) for the Treatment of ADHD in Adults (141KB PDF)
25 Jun 2007 Shire Demonstrates Commitment To Improving Patient Adherence In End Stage Renal Disease As New Phosphate-Binder FOSRENOL® Launches In Europe (52KB PDF)
25 Jun 2007 Notification of major interests in shares (36KB PDF)
21 Jun 2007 Shire Receives Approvable Letter from FDA for INTUNIV™ (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD (34KB PDF)
20 Jun 2007 Shire in-licenses JUVISTA® (human TGFβ3) from Renovo (125KB PDF)
20 Jun 2007 Notification of major interests in shares (34KB PDF)
20 Jun 2007 Results of the Annual General Meeting (21KB PDF)
20 Jun 2007 Annual Information Update (33KB PDF)
19 Jun 2007 Goldman Sachs Group and its holdings in Shire (33KB PDF)
01 Jun 2007 Total Voting Rights (18KB PDF)
29 May 2007 Block Listing Six Monthly Return (72KB PDF)
22 May 2007 Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities (21KB PDF)
19 May 2007 FDA Issues Approvable Letter for SPD465 (Triple-Bead Mixed Amphetamine Salts) for the Treatment of ADHD in Adults
18 May 2007 Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities (27KB PDF)
14 May 2007 Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting (36KB PDF)
11 May 2007 Shire welcomes early date for Judicial Review of NICE decision on Alzheimer’s treatments (23KB PDF)
11 May 2007 Retirement of Non-Executive Director and notification of the Exercise of an Option and Sale of Shares (32KB PDF)
08 May 2007 Shire plc announces the Exercise of Over-Allotment Option in relation to Convertible Bond Offering outside the United States and to non-US persons only (21KB PDF)
03 May 2007 VYVANSE™ (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD (37KB PDF)
03 May 2007 VYVANSE™ (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD (37KB PDF)
02 May 2007 Shire announces the Pricing of US$1,000 million Convertible Bonds due 2014 to be offered outside the United States and to non-US persons only (24KB PDF)
02 May 2007 Shire announces refinancing of bank facilities connected with the recent acquisition of New River through the launch of US$1,000 million Convertible Bonds due 2014 to be offered outside the United States and to non-US persons only (25KB PDF)
01 May 2007 Total Voting Rights (18KB PDF)
25 Apr 2007 First quarter results - strong start to the year with upgraded guidance now including New River (103KB PDF)
20 Apr 2007 Shire Completes Acquisition of New River (18KB PDF)
18 Apr 2007 Shire Successfully Completes Tender Offer for New River Shares (23KB PDF)
17 Apr 2007 FIRST QUARTER 2007 RESULTS DATE NOTIFICATION (20KB PDF)
16 Apr 2007 Results of Extraordinary General Meeting held on 16 April 2007 (26KB PDF)
16 Apr 2007 Notification of major interests in shares (59KB PDF)
10 Apr 2007 Purchase of Shares by Employee Benefit Trust (28KB PDF)
05 Apr 2007 Purchase of Shares by Employee Benefit Trust (18KB PDF)
05 Apr 2007 Movement of shares out of the Employee Benefit Trust (18KB PDF)
04 Apr 2007 Shire Executive Annual Incentive Plan (34KB PDF)
04 Apr 2007 Purchase of Shares by Employee Benefit Trust (18KB PDF)
04 Apr 2007 Movement of shares out of the Employee Benefit Trust (18KB PDF)
03 Apr 2007 Purchase of Shares by Employee Benefit Trust (18KB PDF)
03 Apr 2007 Application for share listing (18KB PDF)
02 Apr 2007 Shire Executive Annual Incentive Plan (18KB PDF)
02 Apr 2007 Total Voting Rights (18KB PDF)
02 Apr 2007 Notification of the Exercise of an Option and Sale of Shares by a Non-Executive Director (18KB PDF)
02 Apr 2007 Purchase of Shares by Employee Benefit Trust (28KB PDF)
29 Mar 2007 Purchase of Shares by Employee Benefit Trust (25KB PDF)
28 Mar 2007 Purchase of Shares by Employee Benefit Trust (28KB PDF)
28 Mar 2007 Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities (27KB PDF)
27 Mar 2007 Judicial Review of NICE decision (29KB PDF)
27 Mar 2007 Purchase of Shares by Employee Benefit Trust (26KB PDF)
26 Mar 2007 Notice of EGM (32KB PDF)
26 Mar 2007 Purchase of Shares by Employee Benefit Trust (28KB PDF)
23 Mar 2007 IFRS results for the year ending December 31, 2006 (100KB PDF)
23 Mar 2007 Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities (18KB PDF)
22 Mar 2007 Holding(s) in Company (60KB PDF)
22 Mar 2007 Holding(s) in Company (70KB PDF)
22 Mar 2007 Notification of the Exercise of an Option and Sale of Shares by a Director (18KB PDF)
22 Mar 2007 Purchase of Shares by Employee Benefit Trust (18KB PDF)
21 Mar 2007 ADDERALL XR® - Shire Files Suit against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf (32KB PDF)
20 Mar 2007 Shire begins external search for President of successful Human Genetic Therapies business, on retirement of David Pendergast at the end of 2007 (23KB PDF)
19 Mar 2007 Shire Announces Expiration of Hart-Scott-Rodino Waiting Period (27KB PDF)
19 Mar 2007 Correction to Purchase of Shares by Employee Benefit Trust (26KB PDF)
16 Mar 2007 Purchase of Shares by Employee Benefit Trust (25KB PDF)
15 Mar 2007 New Human Cell-Produced Treatment for Anaemia Associated with Chronic Kidney Disease Now Available, Shire’s launch of DYNEPO® (epoetin delta) begins across Europe (52KB PDF)
15 Mar 2007 Purchase of Shares by Employee Benefit Trust (18KB PDF)
14 Mar 2007 Purchase of shares by employee benefit trust (26KB PDF)
13 Mar 2007 Purchase of Shares by Employee Benefit Trust (25KB PDF)
12 Mar 2007 Purchase of Shares by Employee Benefit Trust (25KB PDF)
09 Mar 2007 Purchase of Shares by Employee Benefit Trust (20KB PDF)
08 Mar 2007 Purchase of Shares by Employee Benefit Trust (18KB PDF)
06 Mar 2007 Purchase of Shares by Employee Benefit Trust (20KB PDF)
06 Mar 2007 Purchase of Shares by Employee Benefit Trust (18KB PDF)
05 Mar 2007 UK launch expands global reach of FOSRENOL® (156KB PDF)
02 Mar 2007 Holding(s) in Company (58KB PDF)
02 Mar 2007 Purchase of Shares by Employee Benefit Trust (18KB PDF)
02 Mar 2007 Purchase of Shares by Employee Benefit Trust (19KB PDF)
28 Feb 2007 Director/PDMR Shareholding (21KB PDF)
28 Feb 2007 Holding(s) in Company (60KB PDF)
28 Feb 2007 Holding(s) in Company (56KB PDF)
28 Feb 2007 Holding(s) in Company (70KB PDF)
28 Feb 2007 Holding(s) in Company (59KB PDF)
28 Feb 2007 Holding(s) in Company (55KB PDF)
27 Feb 2007 Movement of shares out of the Employee Benefit Trust (17KB PDF)
23 Feb 2007 FDA Approval of VYVANSE™ as a Novel Treatment for ADHD (45KB PDF)
23 Feb 2007 Director/PDMR Shareholding (27KB PDF)
23 Feb 2007 Employee Benefit Trust announcement (26KB PDF)
22 Feb 2007 FOSRENOL® launches in United Kingdom today (112KB PDF)
22 Feb 2007 Director/PDMR Shareholding (18KB PDF)
20 Feb 2007 Shire agrees to acquire new river to gain full control of Vyvanse™, its future flagship product for ADHD (52KB PDF)
20 Feb 2007 Shire announces $800 million equity financing in connection with Acquisition Of New River (18KB PDF)
20 Feb 2007 Result of equity placing (21KB PDF)
20 Feb 2007 Results for the twelve months to December 31, 2006 - On time execution of operating plan delivers strong 2006 performance (207KB PDF)
15 Feb 2007 Total Voting Rights (18KB PDF)
14 Feb 2007 Full Year 2006 Results Date Notification - 23 February 2007 (20KB PDF)
12 Feb 2007 Movement of shares out of the Employee Benefit Trust (18KB PDF)
25 Jan 2007 Goldman Sachs Group and its holdings in Shire (17KB PDF)
23 Jan 2007 Shire licenses the North American rights for SPD754 (19KB PDF)
18 Jan 2007 Total Voting Rights (25KB PDF)
12 Jan 2007 Goldman Sachs Group and its holdings in Shire (17KB PDF)
11 Jan 2007 ELAPRASE® for the treatment of Hunter syndrome approved by the European Commission (28KB PDF)

Did you know...

You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.

Email and SMS alerts

Did you know...

We donated over $35,000 in
outdated laboratory
equipment
to local
schools?